U.S. markets closed
  • S&P Futures

    3,829.00
    +3.50 (+0.09%)
     
  • Dow Futures

    30,965.00
    +32.00 (+0.10%)
     
  • Nasdaq Futures

    11,686.50
    +12.25 (+0.10%)
     
  • Russell 2000 Futures

    1,739.70
    +1.40 (+0.08%)
     
  • Crude Oil

    111.63
    -0.13 (-0.12%)
     
  • Gold

    1,822.20
    +1.00 (+0.05%)
     
  • Silver

    20.78
    -0.03 (-0.12%)
     
  • EUR/USD

    1.0532
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    3.2060
    +0.0120 (+0.38%)
     
  • Vix

    28.36
    +1.41 (+5.23%)
     
  • GBP/USD

    1.2205
    +0.0021 (+0.17%)
     
  • USD/JPY

    136.0770
    -0.0510 (-0.04%)
     
  • BTC-USD

    20,329.10
    -364.84 (-1.76%)
     
  • CMC Crypto 200

    440.78
    -9.28 (-2.06%)
     
  • FTSE 100

    7,323.41
    +65.09 (+0.90%)
     
  • Nikkei 225

    26,737.99
    -311.48 (-1.15%)
     

Agilent (A) to Attract Biopharma Customers With APC Tie-Up

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Agilent Technologies A is consistently building partnerships to provide advanced technological solutions to its customers.

This is evident from the fact that Agilent recently tied up with APC Ltd., a provider of innovative small molecule and large molecule process design and process development solutions.

Per the terms, both companies will offer unique workflows to customers by combining their technologies.

The technologies-enabled workflows will support automated process analysis via liquid chromatography (LC).

On the back of this collaboration, Agilent aims to help customers in the biopharmaceutical and pharmaceutical industry develop higher quality drugs faster.

This is expected to help A gain momentum across customers in the underlined industry, which in turn, is likely to contribute to top-line growth in the days ahead.

Agilent Technologies, Inc. Price and Consensus

Agilent Technologies, Inc. Price and Consensus
Agilent Technologies, Inc. Price and Consensus

Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote

Teeming Prospects

The recent partnership is anticipated to help A expand its presence in the booming biopharmaceutical market.

The biopharmaceutical market has been significantly growing of late owing to the increasing number of geriatric population and the rising chronic diseases. Further, the ongoing coronavirus pandemic is prompting the biopharmaceutical companies to develop COVID-related vaccines, thus creating growth in this market.

Per the Mordor Intelligence report, the underlined market is expected to reach $534.2 billion by 2027, witnessing a CAGR of 7.32% between 2022 and 2027.

Further, the latest collaboration might aid Agilent penetrate the increasing pharmaceutical market which is likely to hit $1.7 trillion by 2025, seeing a CAGR of 8% from 2021 to 2025, per a Research and Markets report.

Solid Portfolio

The recent alliance bodes well for Agilent as it makes consistent efforts to strengthen its portfolio offerings.

Recently, A incorporated advanced artificial intelligence technology developed by Virtual Control into its gas chromatography and mass spectrometry platforms to enhance lab productivity.

In addition, Agilent released the Agilent Seahorse XF Pro Analyzer, featuring new pharma-oriented workflow solutions incorporating advanced experimental design and analysis tools.

The introductionof the Agilent 8697 Headspace Sampler with integrated gas chromatography communication in the pharmaceutical space remains a positive.

We believe that these endeavors will continue to benefit Agilentin gaining strong momentum in the various end-markets that it serves.

Zacks Rank & Other Stocks to Consider

Currently, Agilent carries a Zacks Rank #2 (Buy). Investors interested in the broader technology sector can also consider stocks like Avnet AVT, Monolithic Power Systems MPWR and MaxLinear MXL. While AVT and MPWR sport a Zacks Rank #1 (Strong Buy), MXL carries a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Avnet has gained 9% in the past year. The long-term earnings growth rate for AVT is currently projected at 37.2%.

Monolithic Power Systems has gained 33.1% in the past year. MPWR’s long-term earnings growth rate is currently projected at 25%.

MaxLinear has gained 3.1% in the past year. The long-term earnings growth rate for MXL is currently projected at 20%.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Avnet, Inc. (AVT) : Free Stock Analysis Report
 
Agilent Technologies, Inc. (A) : Free Stock Analysis Report
 
Monolithic Power Systems, Inc. (MPWR) : Free Stock Analysis Report
 
MaxLinear, Inc (MXL) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research